Newsletter Tool

PM Tracker

Today’s Big News

Jun 13, 2025

Sens. Sanders, King propose legislation to ban direct-to-consumer ads for prescription drugs

BMS taps biotech analyst from Goldman Sachs to lead long-term strategy

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients

Atraverse Medical raises $29.4M for left-heart access system

AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

Featured

Sens. Sanders, King propose legislation to ban direct-to-consumer ads for prescription drugs

By Kevin Dunleavy

Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical companies from advertising directly to consumers. The End Prescription Drug Ads Now Act would prohibit drugmakers from promoting prescription drugs through television, radio, print, digital platforms and social media.

BMS taps biotech analyst from Goldman Sachs to lead long-term strategy

By Darren Incorvaia

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9.

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients

By Darren Incorvaia

Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program.

Atraverse Medical raises $29.4M for left-heart access system

By Conor Hale

Founded by the same group that helped launch the pulsed field ablation company Farapulse, Atraverse Medical plans to expand its commercial reach.

AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases

By James Waldron

AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote

By Zoey Becker

Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care.

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

By James Waldron

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies.

Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation

By Angus Liu

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.

Chutes & Ladders—Sanofi vaccine vet vaults to GSK

By Darren Incorvaia,Zoey Becker

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan will head up the British Big Pharma’s vaccine and infectious disease R&D from Boston, working under Chief Scientific Officer Tony Wood, Ph.D.

Regulatory tracker: Moderna's RSV vaccine picks up wider FDA nod

By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

Fierce podcasts